[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":212},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,65,85,111,137,166,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638007","acupuncture-for-heel-pain-syndrome-a-multicenter-randomized-controlled-trial-100638007",false,"NCT07607223","Acupuncture for Heel Pain Syndrome: A Multicenter Randomized Controlled Trial","Clinical Research on Acupuncture at the Heel Pain Point for the Treatment of Heel Pain Syndrome","Inclusion Criteria:\n\n1. Meeting the aforementioned Western medicine diagnostic criteria for heel pain.\n2. Aged 40-70 years with a disease duration of less than two months and no prior relevant treatments.\n3. Voluntary provision of informed consent and willingness to receive the corresponding treatments.\n4. Presence of calcaneal spurs on X-ray radiography is permitted.\n\nExclusion Criteria:\n\n1. Presence of gout, trauma, osteomyelitis, or purulent inflammation in the affected area.\n2. Concomitant history of heel trauma with localized redness, swelling, heat, and inflammatory reactions.\n3. Chronic conditions that may confound treatment efficacy or outcome interpretation (e.g., cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, dementia, epilepsy, or other disqualifying conditions).\n4. Radicular pain accompanied by lower extremity muscle weakness, sensory loss, diminished reflexes, progressive neurological deficits, or severe neurological symptoms.\n5. Contraindications to acupuncture (e.g., hemorrhagic diseases, coagulopathy, history of anticoagulant therapy, severe diabetes with infection risk, severe cardiovascular disease).\n6. History of adverse reactions to acupuncture or alcohol allergies.\n7. Currently pregnant or planning to conceive.\n8. Deemed unsuitable for study inclusion by the investigators.","ALL","40 Years","70 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The main goal of this study is to determine if a specific acupuncture technique-targeting a \"heel pain point\" located on the hand-is an effective and safe way to treat heel pain. Specifically, the researchers want to:\n\nMeasure Pain Relief: Evaluate how effectively the treatment reduces pain levels.\n\nCheck Physical Function: Determine if the treatment helps patients walk and move more comfortably.\n\nEnsure Safety: Track any side effects or adverse reactions to confirm the treatment is safe for patients.\n\nTarget Population\n\nThe study is looking for participants who meet the following criteria:\n\nAge: Adults between 40 and 70 years old. Diagnosis: Individuals diagnosed with heel pain (plantar fasciitis). Duration: People who have had the pain for less than two months and have not recently received other related treatments.\n\nTypical Symptoms: Individuals who experience significant pain during their first few steps in the morning or after sitting for a long time.\n\nExclusions: The study excludes people with recent foot injuries, gout, or serious underlying health conditions such as severe diabetes or heart disease.\n\nPrimary Research Endpoint\n\nThe \"Primary Endpoint\" is the specific result the researchers use to decide if the treatment was successful:\n\nThe 50% Reduction Goal: The study measures the \"response rate,\" which is the percentage of patients whose pain score decreases by at least 50% compared to their starting pain level.\n\nEvaluation Timing: This success measure is evaluated after the patient completes one full course of treatment, which consists of 10 sessions given over approximately 20 days.",[27],"Heel Pain Syndrome","NOT_YET_RECRUITING","2026-05-19",{"date":31,"type":32},"2026-05-26","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2027-10-30",{"name":38,"class":39},"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100634077","phase-3-a-prospective-multicenter-randomized-parallel-controlled-superiority-trial-100634077","NCT07534995","A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Trial","A Randomized Controlled Clinical Study of Shouhui Tongbian Capsule in the Treatment of Opioid-Induced Constipation","Inclusion Criteria:\n\n1. Must meet the diagnostic criteria for \\*\\*opioid-induced constipation (OIC) according to the Rome IV Criteria\\*\\*.\n2. Patients enrolled in the trial must have a history of OIC symptoms for at least 1 week.\n3. Patients must be aged ≥ 18 years and ≤ 85 years.\n4. Patients must have stable cancer status with a life expectancy of more than 6 months.\n5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n6. Patients must be on a relatively stable maintenance regimen of opioids, including a daily morphine-equivalent dose of 30 mg to 1000 mg for at least 2 weeks prior to the screening period. In addition, opioid therapy is expected to continue for at least 10 weeks.\n7. Patients must have a spontaneous bowel movement (SBM) frequency of ≤ 2 times per week without laxative use.\n8. Patients must be able to take medications, food, and fluids orally.\n9. Voluntarily participate in the trial and have signed the informed consent form.\n10. No use of any prokinetic agents for at least 1 week prior to randomization.\n\nExclusion Criteria:\n\n1. Patients diagnosed with clinically significant defecation disorders at enrollment caused by structural abnormalities of the gastrointestinal tract and other gastrointestinal-related tissues (excluding OIC): inflammatory bowel disease, rectal prolapse, gastrointestinal obstruction, peritoneal metastasis or peritoneal tumors.\n2. Patients with a history of gastrointestinal surgery, abdominal surgery or abdominal adhesions within 1 month before screening; or a history of intestinal obstruction within 3 months before screening.\n3. Diagnosis of active diverticular disease; or severe hemorrhoids; or anal fissure; or artificial rectum or anus.\n4. Patients with intra-abdominal catheters or feeding tubes.\n5. Diagnosis of pelvic diseases considered to significantly affect intestinal transit of feces (e.g., uterine prolapse ≥ grade 2, uterine fibroids \\[located posteriorly with diameter ≥ 5 cm\\] affecting defecation).\n6. Patients who received a new chemotherapy regimen never used before within 14 days after screening, or who planned to receive such treatment during the study period.\n7. Patients who received radiotherapy within 28 days after screening or planned to receive such treatment during the study period.\n8. Patients who underwent surgery or intervention considered to significantly affect gastrointestinal function within 28 days after screening, or planned to undergo such surgery or intervention during the study period, or planned to undergo surgery or intervention expected to prevent completion of the trial.\n9. Patients with uncontrolled hyperthyroidism, severe hypertension, heart disease, systemic infection or coagulation disorders (hypercoagulable state or bleeding tendency) at study enrollment.\n10. Patients who took \\>4 additional opioid doses per day for breakthrough pain for more than 3 days during the baseline period, or who modified the maintenance opioid dosing regimen during this period.\n11. Patients with severe cancer pain unresponsive to opioid therapy at regular doses and frequencies (e.g., typical mean daily pain intensity rating of 7 to 10 on the Numerical Rating Scale (NRS; 0 \\[no pain\\] to 10 \\[worst possible pain\\])).\n12. Patients with a history of opioid discontinuation due to serious adverse events, or for whom opioid discontinuation is anticipated due to potential risk of adverse events.\n13. Patients treated with opioid receptor antagonists within 1 month before screening.\n14. Unconsciousness, psychosis, or inability to express subjective symptoms.\n15. Patients who have participated in or are participating in other clinical trials within the past 3 months.\n16. Other patients considered ineligible for the study by the investigator based on concomitant treatments and medical findings.","18 Years","85 Years",{"count":51,"type":21},270,[53],"PHASE3","This study intends to design and conduct a prospective, multicenter, randomized, parallel-controlled, superiority trial to evaluate the symptom-relieving effects of Shouhui Tongbian Capsule on opioid-induced constipation (OIC) in cancer patients, including defecation frequency, stool consistency, symptom scores, quality of life and other indicators, and to systematically observe its safety in clinical application. Through analysis of intestinal flora, the mechanism of Shouhui Tongbian Capsule in regulating intestinal function will be revealed. By screening the optimal population for Shouhui Tongbian Capsule in the treatment of OIC, evidence will be provided for optimizing individualized medication.\n\nThe primary efficacy endpoint is the proportion of responders at week 2 of treatment, defined as an increase of ≥1 in the average weekly number of spontaneous bowel movements (SBMs) compared with baseline and at least one SBM during that week. Secondary endpoints include weekly number of SBMs, weekly number of complete spontaneous bowel movements (CSBMs), Bristol Stool Form Scale score, straining score, Patient Assessment of Constipation-Symptoms (PAC-SYM) score, and Patient Assessment of Constipation-Quality of Life (PAC-QOL) score.\n\nSafety endpoints mainly include the incidence of adverse events and changes in vital signs, electrocardiography, routine blood and urine tests, as well as liver and renal function before and after treatment. Meanwhile, based on clinical study data, the characteristics of the optimal population for Shouhui Tongbian Capsule in treating OIC will be identified to further enrich the application scenarios of this capsule for OIC.",[56],"OIC","2026-04-22",{"date":59,"type":32},"2026-04-27",{"date":61,"type":21},"2026-05-30",{"date":63,"type":21},"2027-12-30",{"name":38,"class":39},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100634937","clinical-study-of-electroacupuncture-for-postoperative-gastroparesis-in-patients-with-digestive-tract-tumors-100634937","NCT07546175","Clinical Study of Electroacupuncture for Postoperative Gastroparesis in Patients With Digestive Tract Tumors","Inclusion Criteria:\n\n1. Aged 18-65 years;\n2. History of digestive system tumor surgery;\n3. Meet the diagnostic criteria for PGS (postoperative gastroparesis syndrome);\n4. Voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n1. Gastroparesis caused by other diseases, such as diabetes mellitus or scleroderma;\n2. Use of medications that affect gastric smooth muscle function, such as morphine or atropine;\n3. Suspected or confirmed history of alcohol addiction or drug abuse, or concomitant cognitive impairment or severe mental illness that precludes cooperation with the clinical study;\n4. Severe organic diseases of vital organs, such as severe chronic obstructive pulmonary disease (COPD), interstitial pneumonia, pulmonary fibrosis, or complicated by respiratory failure; renal insufficiency or glomerulosclerosis; or severe disturbances of fluid, electrolyte, or acid-base balance;\n5. Women who are pregnant, breastfeeding, or planning to become pregnant.","65 Years",{"count":73,"type":21},76,[24],"This study aims to design and conduct a prospective, multicenter, randomized, parallel-controlled, sham-controlled clinical trial to evaluate the clinical efficacy of electroacupuncture for postsurgical gastroparesis syndrome (PGS) after digestive tract tumor surgery and systematically assess its clinical safety. By measuring gastrointestinal hormones, inflammatory factors, proteomics and metabolomics, we intend to explore the mechanism underlying the improvement of postoperative gastrointestinal motility by electroacupuncture. We will identify the optimal population for electroacupuncture in PGS by analyzing baseline characteristics and efficacy correlations, to provide evidence for individualized clinical intervention. The primary endpoint is the Daily Diary of Gastroparesis Cardinal Symptom Index (GCSI-DD) score at Day 14 of treatment. Finally, based on clinical data, this study will define the eligible population and optimal protocol of electroacupuncture for PGS, and further standardize and promote its clinical application in postoperative complications of cancer.",[77],"PGS","2026-04-20",{"date":57,"type":32},{"date":81,"type":21},"2026-04-14",{"date":83,"type":21},"2028-12-31",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":93,"minAge":48,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100630689","electroacupuncture-vs-auricular-acupressure-vs-waitlist-control-for-breast-cancer-endocrine-therapy-related-joint-pain-100630689","NCT07490938","Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain","Electroacupuncture Versus Auricular Acupressure Versus WaitliSt Control for Endocrine Therapy-related Joint Pain in Patients With Breast Cancer (EASE): A Pragmatic Multicenter Randomised Controlled Trial","EASE","Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer, stage I-IV, according to the AJCC Cancer Staging Manual (8th edition);\n* Aged 18-75 years;\n* Experiencing joint pain attributed to endocrine therapy, including localized or generalized joint pain, with symptoms persisting for at least 1 week;\n* Completion of all planned surgeries, chemotherapy, and radiotherapy, with a scheduled continuation of endocrine therapy for at least 1 additional year;\n* Self-reported worst joint pain score of ≥3 on a 0-10 Visual Analogue Scale (VAS) during the past week;\n* Life expectancy ≥1 year;\n* Voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n* Bone metastases involving the same site as the affected joint attributed to endocrine therapy;\n* History of fracture or surgery involving the affected joints within the past 6 months;\n* Implanted electronic medical devices;\n* Not suitable for acupuncture, including but not limited to bleeding tendencies (e.g. coagulation disorders or purpura) or local skin lesions at the intended acupoint sites.","FEMALE","75 Years",{"count":96,"type":21},200,[24],"The purpose of this pragmatic, multicenter, randomized controlled trial is to evaluate the clinical effectiveness and safety of electroacupuncture and auricular acupressure for improving joint pain related to endocrine therapy in breast cancer patients. A total of 200 participants will be recruited and randomly assigned to one of three groups: the Electroacupuncture Group (n=80), the Auricular Acupressure Group (n=80), or the Waitlist Control Group (n=40), using a central stratified block randomization method.\n\nThe primary objective is to compare changes in Worst Pain Item score among the three groups from baseline to the end of the treatment period, as measured by the Brief Pain Inventory-Short Form (BPI-SF). Secondary objectives include assessing pain interference, overall health status through the PROMIS scale, and quality of life specifically related to endocrine therapy using the FACT-ES. Additionally, the study will evaluate analgesic medication use (QAQ), patient expectations (Acupuncture Expectancy Scale), treatment adherence, and the occurrence of adverse events. By comparing these interventions, this study aims to generate high-quality evidence for the management of treatment-related arthralgia in breast cancer survivors.",[100,101],"Breast Cancer Survivors","Endocrine Therapy-Induced Joint Pain","2026-03-31",{"date":104,"type":32},"2026-04-06",{"date":106,"type":21},"2026-04",{"date":108,"type":21},"2027-12",{"name":38,"class":39},4,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":40},"100630917","acupuncture-for-post-stroke-dysphagia-a-clinical-study-100630917","NCT07493902","Acupuncture for Post-Stroke Dysphagia: A Clinical Study","Acupuncture Treatment for Post-Stroke Dysphagia: A Prospective, Multicenter Clinical Study of a Cohort-Based Embedded Partially Randomized Preference Trial","Inclusion Criteria:\n\n* Age between 18 and 80 years old, no gender restrictions;\n\n  * Meets diagnostic criteria for ischemic or hemorrhagic stroke, confirmed by CT or MRI, with disease duration within one year;\n\n    * Meets diagnostic criteria for dysphagia, with FOIS grade 2-4;\n\n      * Vital signs stable, able to understand and cooperate with study procedures; ⑤ Patient or legal representative agrees to sign informed consent.\n\nExclusion Criteria:\n\n* Dysphagia not caused by stroke, but resulting from other neurological disorders (e.g., motor neuron disease, myasthenia gravis) or organic lesions (e.g., tumors);\n\n  * Patients with psychiatric disorders or severe cognitive impairment who cannot cooperate with treatment;\n\n    * Patients with an expected survival time of less than 3 months; ④ Individuals with contrast medium allergy;\n\n      * Patients with severe needle phobia who cannot tolerate the procedure; ⑥ Pregnant women, those planning pregnancy, or lactating women; ⑦ Individuals who have participated in other clinical trials or received acupuncture within the past week.","80 Years",{"count":120,"type":21},3232,[24],"Employing a nested design, a partially randomized preference study (Study II) is embedded within a prospective, multicenter cohort study (Study I). The cohort study, with acupuncture as the exposure factor, explores the clinical efficacy and health economic value of different integrated Chinese and Western medicine treatment protocols. The nested partially randomized preference study of different acupuncture protocols generates high-level evidence through randomized cohorts while supplementing real-world decision-making with preference cohort data.",[124,125],"Post-stroke Dysphagia","Acupuncture",[127,128],"post-stroke dysphagia","acupuncture","RECRUITING","2026-03-20",{"date":132,"type":32},"2026-03-25",{"date":106,"type":21},{"date":135,"type":21},"2028-04",{"name":38,"class":39},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":93,"minAge":48,"maxAge":94,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":155,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100629994","effect-of-acupuncture-on-psychoneurological-symptom-cluster-in-breast-cancer-survivors-100629994","NCT07481903","Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors","Inclusion Criteria：\n\n1. Female, aged 18-75 years;\n2. Histologically confirmed Stage 0, I, II, or III breast cancer (according to the AJCC 8th edition)；\n3. Completed active treatment (surgery, chemotherapy, and\u002For radiotherapy) at least 1 month prior to study initiation , and are currently receiving endocrine therapy；\n4. Meet at least 2 of the following 6 criteria:\n\n(1)Visual Analogue Scale (VAS) score for pain ≥ 4 (2)Pittsburgh Sleep Quality Index (PSQI) score ≥ 8 (3)Brief Fatigue Inventory-Chinese version (BFI-C) score ≥ 4 (4)Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) score ≥ 8 (5)Hospital Anxiety and Depression Scale-Depression subscale (HADS-D) score ≥ 8 (6)Functional Assessment of Cancer Therapy-Cognitive Function-Perceived Cognitive Impairments (FACT-Cog-PCI) score \\\u003C 60 ; 5.Has signed the informed consent form and voluntarily participates in this study.\n\nExclusion Criteria:\n\n1. History of psychiatric disorders (e.g., bipolar disorder, schizophrenia, substance addiction)\n2. Presence of diseases that may impair cognitive function or interfere with study assessments (e.g., Alzheimer's disease, Parkinson's disease, brain tumors).\n3. Fatigue attributable to a treatable condition (e.g., hypothyroidism).\n4. Severe debilitation or significant organic disease (e.g., heart failure, severe hepatic\u002Frenal insufficiency, severe anemia, uncontrolled infection).\n5. Use of anxiolytics, antidepressants, psychostimulants, or sedative-hypnotics within the past 4 weeks.\n6. Chronic use of corticosteroids.\n7. Prior acupuncture treatment within 3 months, or participation in an acupuncture or drug clinical trial within 6 months.\n8. History of hemorrhagic disease, severe coagulation dysfunction, or current use of anticoagulants (e.g., warfarin).\n9. Implanted cardiac pacemaker.\n10. Pregnancy or breastfeeding.\n11. Concurrent participation in another clinical study.",{"count":144,"type":21},228,[24],"This clinical trial aims to assess whether electroacupuncture (EA) can alleviate the psychoneurological symptom cluster (including pain, fatigue, insomnia, anxiety, depression and subjective cognitive decline) in breast cancer survivors, and to evaluate the safety of this therapy.\n\nResearchers will conduct a randomized controlled trial of electroacupuncture (EA) as compared to sham electroacupuncture (SA) in breast cancer survivors with the psychoneurological symptom cluster who are currently being treated with endocrine therapy.\n\nParticipants will receive 16 treatments over 8 weeks. The EA group will receive true acupuncture with continuous wave stimulation (2Hz, intensity as tolerated) administered for 30 minutes per session. The SA group will receive sham acupuncture using blunt (non-penetrating) needles that contact the skin without penetration, along with a 30-second transient device activation instead of the 30-minute continuous stimulation.\n\nTreatment outcomes for pain, fatigue, insomnia, anxiety, depression and subjective cognitive function will be assessed. The primary outcome is response rate of the psychoneurological symptom cluster after 8 weeks of treatment. Secondary outcomes include changes from baseline in the scores of each of the six psychoneurological symptoms.",[148,149,150,151,152,153,154],"Psychoneurological Symptom Cluster(Pain, Insomnia, Anxiety, Fatigue, Depression, Subjective Cognitive Decline)","Pain","Insomnia","Anxiety","Fatigue","Depression","Subjective Cognitive Decline (SCD)",[156,157,125],"Psychoneurological Symptom Cluster","Breast Cancer","2026-03-15",{"date":160,"type":32},"2026-03-19",{"date":106,"type":21},{"date":163,"type":21},"2028-07",{"name":38,"class":39},6,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100613140","association-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-with-post-stroke-pneumonia-a-real-world-retrospective-cohort-study-100613140","NCT07262710","Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","Inclusion Criteria:\n\n1. Diagnosis of both stroke and hypertension, with the initial diagnosis dates for both conditions falling within the period from January 1, 2016, to December 31, 2024.Definition of Stroke: International Classification of Diseases, 10th Revision (ICD-10) codes I60-I64, or a primary diagnosis of stroke-related conditions in inpatient\u002Foutpatient medical records, including but not limited to: cerebral hemorrhage, hemorrhagic stroke, cerebral infarction, ischemic stroke, cerebral ischemia, brainstem infarction.Definition of Hypertension: ICD-10 code I10, or inpatient\u002Foutpatient medical records containing diagnostic names such as hypertension, benign hypertension, hypertensive crisis.\n2. At least one prescription filled from any of the five major classes of antihypertensive medications: Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin II Receptor Blockers (ARB), Beta-blockers, Calcium Channel Blockers (CCB), or Diuretics. Furthermore, there must be no record of any ACEI, ARB, or CCB prescriptions within the 12 months immediately preceding the first ACEI, ARB, or CCB prescription.\n3. Aage ≥18 years.\n\nExclusion Criteria:\n\n1. Data anomalies or errors(such as an inaccurately recorded date of death).\n2. Concurrent use of two or three drug classes among ACEI, ARB, and CCB at any time.\n3. Any recorded diagnosis of pneumonia prior to the initiation of the first antihypertensive medication.Definition of Pneumonia: ICD-10 codes J12-J18 or J69, or inpatient\u002Foutpatient medical records containing diagnostic names such as pulmonary infection, pneumonia, lung infection.",{"count":173,"type":21},13656,"OBSERVATIONAL","The goal of this retrospective cohort study is to determine if Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) can lower the risk of post-stroke pneumonia. With an active comparator, new-user design, we selected new users of Calcium Channel Blockers (CCBs) as the reference group to compare against new users of ACEIs\u002FARBs.",[177],"Post-stroke Pneumonia",[179,180,181],"post-stroke pneumonia","angiotensin converting enzyme inhibitors","angiotensin receptor blockers","2025-11-23",{"date":184,"type":32},"2025-12-04",{"date":186,"type":21},"2025-12-01",{"date":188,"type":21},"2026-08-19",{"name":38,"class":39},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":71,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100607907","study-on-the-immediate-analgesic-effect-of-yanglingquan-acupoint-treatment-for-biliary-colic-100607907","NCT07194655","Study on the Immediate Analgesic Effect of Yanglingquan Acupoint Treatment for Biliary Colic","Inclusion Criteria:\n\n* Meets diagnostic criteria for cholecystitis according to both Chinese and Western medicine;\n* Patients exhibiting clinical manifestations of biliary colic with a Visual Analogue Scale (VAS) score \\>4;\n* Aged 18 to 65 years;\n* Patients provide informed consent and voluntarily participate in this study.\n\nExclusion Criteria:\n\n* Patients meeting criteria for emergency surgery;\n* Patients with psychiatric issues unable to cooperate with treatment;\n* Patients with severe complications such as suppurative cholecystitis, suppurative cholangitis, acute pancreatitis, gallbladder perforation, tumors, or severe infections;\n* Patients with other serious comorbidities including liver, brain, kidney, or cardiovascular diseases;\n* Patients with severe local lesions (e.g., infections, burns, scalds) where acupuncture is contraindicated;\n* Pregnant women and lactating women;\n* Patients who have already undergone other treatment modalities.",{"count":197,"type":21},248,[24],"Guided by traditional meridian and acupoint theory, conducting standardized, large-sample, multicenter randomized controlled trials (RCTs) to evaluate the clinical efficacy of pattern differentiation and meridian-based acupoint selection for biliary colic across multiple levels can provide high-quality research evidence for developing evidence-based guidelines or optimal treatment protocols. This holds significant importance for enhancing the clinical efficacy of acupuncture in treating biliary colic and promoting its widespread clinical application. Therefore, this study will conduct a multicenter, large-sample randomized controlled trial comparing the clinical effects of acupuncture at Yanglingquan (GB34) versus drug therapy for acute cholecystitis biliary colic. It aims to investigate the clinical efficacy and safety of acupuncture treatment for acute cholecystitis biliary colic.",[201],"Biliary Colic",[203],"Biliary colic","2025-09-24",{"date":206,"type":32},"2025-09-26",{"date":208,"type":21},"2025-10",{"date":210,"type":21},"2026-10",{"name":38,"class":39},""]